Abiopharma

News list

Director Rothman Paul 🟢 acquired 1.9K shares (1 derivative) of Merck & Co., Inc. (MRK) Transaction Date: May 29, 2026 | Filing ID: 000157

Full text

News bot June 2, 2026, 6:14 p.m.
🔍 Rothman Paul (Director)

Company: Merck & Co., Inc. (MRK)

Report Date: 2026-05-29
Transaction Summary:
- Total transactions: 2
- Derivative instruments: 1
- Holdings reported: 1
- Total shares acquired: 1,853
- Total shares held: 100
Detailed Transactions and Holdings:
- Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-29 | Code: H | shares_owned_after: 100.00
- Acquired 1,853 shares of Phantom Stock (Derivative)
  Date: 2026-05-29 | Code: A | equity_swap_involved: 0 | shares_owned_after: 34,944.94 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3
Footnotes:
- F1: 1-for-1
- F2: Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation.
- F3: Holdings include shares acquired in dividend reinvestment transactions.